Many factors must be considered and discussed with women when initiating a contraceptive
method and the risk of venous thromboembolism (VTE) is one of them. In this review, we …

Introduction Estrogens used in women's healthcare have been associated with increased
risks of venous thromboembolism (VTE) and breast cancer. Estetrol (E4), an estrogen …

Estetrol (E4) is a natural estrogenic steroid that is normally produced by human fetal liver.
Recent research has demonstrated that it is a potent, orally bioavailable, natural selective …

Objectives To evaluate the effect on endocrine and metabolic parameters of a new
combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) …

Migraine is a major neurological disorder affecting one in nine adults worldwide with a
significant impact on health care and socioeconomic systems. Migraine is more prevalent in …

Objective To assess efficacy, cycle control, and safety of an oral contraceptive containing
estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg. Study design Women aged 16 to 50 …

Background: The use of oral contraceptives (OCs) is associated with an increased risk of
cardiovascular events such as arterial and venous thrombosis (VTE). Cardiovascular …

Estetrol/drospirenone is a combined oral contraceptive (COC) with a plant-synthesised
foetal oestrogen (estetrol) and a well-established progestin (drospirenone). In preclinical …

The spironolactone derivative drospirenone is combined with ethinylestradiol or estetrol in
combined oral contraceptives. Formulations with 17-β-estradiol are used to treat climacteric …

Objective To compare the impact on thrombin generation of the new combined oral
contraceptive containing 15 mg estetrol and 3 mg drospirenone with ethinylestradiol (30 or …